asa glp-1 agonist guidelines How should we approach patients on agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the and Decoding the Enigma: Strategies for Anesthetic Management of Patients on Glucagon-Like The New Weight Management Meds

Antibody development was not associated with decreased effectiveness, but it was associated with an increase in hypersensitivity and injection site reactions (6.2% and 11.3%, respectively)

So this is going to be things like quercetin, which is found in blackberries, blueberries, dark cherries, grapes, apples, and red wine, curcumin, which is a compound that's found in turmeric, resveratrol found in grapes, wine, cacao and berries, and then also EGCG, which is found in matcha or green tea

Collectively, these insights position GLP-1 and its analogs as versatile and promising agents in the broader context of metabolic disease management

Thus, the elucidation of whether the SGLT2-i diuretic effect can influence ARR values for PA screening in patients with diabetes and hypertension is an important clinical issue

JAMA (2019) 321:1457

These are all partially correct, but none capture the full picture